Together, these findings suggest that selective participation of c-Jun with c-Fos-Fra-2 protein complex of AP-1 plays an important role in maintaining undifferentiated tumor phenotype, aggressiveness and poor prognosis that may lead to drug resistance, treatment failure and disease relapse. The gene discussed is FOS; the disease is neoplasm.